Josune Orbe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/622476/publications.pdf

Version: 2024-02-01

117571 175177 3,252 95 34 52 h-index citations g-index papers 110 110 110 4908 times ranked docs citations citing authors all docs

#	Article	IF	Citations
1	C-Reactive Protein Induces Matrix Metalloproteinase-1 and -10 in Human Endothelial Cells. Journal of the American College of Cardiology, 2006, 47, 1369-1378.	1.2	168
2	The CD163-expressing macrophages recognize and internalize TWEAK. Atherosclerosis, 2009, 207, 103-110.	0.4	129
3	Identification of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 916-922.	1.1	127
4	Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Critical Care, 2009, 13, R158.	2.5	105
5	Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clinical Biochemistry, 2002, 35, 315-320.	0.8	99
6	Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis, 2003, 170, 269-276.	0.4	98
7	Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease. Scientific Reports, 2019, 9, 15580.	1.6	91
8	Preliminary characterisation of the promoter of the human p22phox gene: identification of a new polymorphism associated with hypertension. FEBS Letters, 2003, 542, 27-31.	1.3	86
9	Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 587-593.	1.1	82
10	Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Frontiers in Bioscience - Landmark, 2008, 13, 2916.	3.0	78
11	Matrix Metalloproteinases in Diabetic Kidney Disease. Journal of Clinical Medicine, 2020, 9, 472.	1.0	65
12	Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. Journal of Thrombosis and Haemostasis, 2007, 5, 91-97.	1.9	62
13	Antioxidant vitamins increase the collagen content and reduce MMP-1 in a porcine model of atherosclerosis: implications for plaque stabilization. Atherosclerosis, 2003, 167, 45-53.	0.4	61
14	Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/Câ€X chemokine receptor 4 axis. Hepatology, 2015, 62, 166-178.	3.6	61
15	Association of Sepsis-Related Mortality with Early Increase of TIMP-1/MMP-9 Ratio. PLoS ONE, 2014, 9, e94318.	1.1	60
16	Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thrombosis and Haemostasis, 2008, 99, 382-387.	1.8	59
17	Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thrombosis and Haemostasis, 2013, 110, 598-608.	1.8	57
18	Matrix Metalloproteinase-10 Effectively Reduces Infarct Size in Experimental Stroke by Enhancing Fibrinolysis via a Thrombin-Activatable Fibrinolysis Inhibitor–Mediated Mechanism. Circulation, 2011, 124, 2909-2919.	1.6	54

#	Article	IF	CITATIONS
19	Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Critical Care, 2011, 15, R97.	2.5	53
20	Synergistic Effect of Thrombin and CD40 Ligand on Endothelial Matrix Metalloproteinase-10 Expression and Microparticle Generation In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1477-1487.	1.1	53
21	Prothrombin Fragment 1+2 Is Associated With Carotid Intima-Media Thickness in Subjects Free of Clinical Cardiovascular Disease. Stroke, 2004, 35, 1085-1089.	1.0	52
22	Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clinica Chimica Acta, 2006, 368, 138-143.	0.5	52
23	A comparison between percutaneous and surgical transplantation of autologous skeletal myoblasts in a swine model of chronic myocardial infarctionâ [†] . Cardiovascular Research, 2006, 71, 744-753.	1.8	52
24	CCL20 Is Increased in Hypercholesterolemic Subjects and Is Upregulated By LDL in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2733-2741.	1.1	47
25	proMetalloproteinaseâ€10 is associated with brain damage and clinical outcome in acute ischemic stroke. Journal of Thrombosis and Haemostasis, 2013, 11, 1464-1473.	1.9	44
26	Matrix metalloproteinaseâ€10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. Liver International, 2014, 34, e257-70.	1.9	43
27	Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. European Heart Journal, 2005, 26, 153-158.	1.0	42
28	Matrix Metalloproteinase-10 Is Upregulated by Thrombin in Endothelial Cells and Increased in Patients With Enhanced Thrombin Generation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2109-2116.	1.1	42
29	Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects. Journal of Thrombosis and Haemostasis, 2005, 3, 662-664.	1.9	40
30	Adipose Stromal Vascular Fraction Improves Cardiac Function in Chronic Myocardial Infarction through Differentiation and Paracrine Activity. Cell Transplantation, 2012, 21, 1023-1037.	1.2	40
31	The Role of Circulating Biomarkers in Peripheral Arterial Disease. International Journal of Molecular Sciences, 2021, 22, 3601.	1.8	40
32	MMP-10 Is Required for Efficient Muscle Regeneration in Mouse Models of Injury and Muscular Dystrophy. Stem Cells, 2014, 32, 447-461.	1.4	39
33	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 78, 1275-1280.	2.6	37
34	The CXCR4/SDF1 Axis Improves Muscle Regeneration Through MMP-10 Activity. Stem Cells and Development, 2014, 23, 1417-1427.	1.1	36
35	Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke. Stroke, 2016, 47, 1312-1318.	1.0	36
36	A Role for MMP-10 (Matrix Metalloproteinase-10) in Calcific Aortic Valve Stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1370-1382.	1.1	36

#	Article	IF	CITATIONS
37	Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease. Journal of Vascular Surgery, 2015, 61, 428-435.	0.6	35
38	Effect of the administration of recombinant hirudin and/or tissue-plasminogen activator (t-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits. British Journal of Haematology, 1999, 105, 117-121.	1.2	34
39	The All66C polymorphism of the ATl receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. Journal of Hypertension, 2003, 21, 2085-2092.	0.3	34
40	Association between Serum Tissue Inhibitor of Matrix Metalloproteinase-1 Levels and Mortality in Patients with Severe Brain Trauma Injury. PLoS ONE, 2014, 9, e94370.	1.1	34
41	Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD). Journal of Extracellular Vesicles, 2020, 9, 1729646.	5.5	34
42	The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis. Critical Care, 2013, 17, R94.	2.5	31
43	Validation of plasma fibrinogen as a marker of carotid atherosclerosis in subjects free of clinical cardiovascular disease. Haematologica, 2004, 89, 1226-31.	1.7	30
44	Regulation by Nitric Oxide of Endotoxin-Induced Tissue Factor and Plasminogen Activator Inhibitor-1 in Endothelial Cells. Thrombosis and Haemostasis, 2002, 88, 1060-1065.	1.8	29
45	Independent Association of Fibrinogen with Carotid Intima-Media Thickness in Asymptomatic Subjects. Cerebrovascular Diseases, 2003, 16, 356-362.	0.8	28
46	Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2009, 297, R1563-R1569.	0.9	27
47	Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification. Atherosclerosis, 2018, 278, 124-134.	0.4	27
48	Combined sustained release of BMP2 and MMP10 accelerates bone formation and mineralization of calvaria critical size defect in mice. Drug Delivery, 2018, 25, 750-756.	2.5	25
49	CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage. Journal of the American Heart Association, 2017, 6, .	1.6	24
50	MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade. Scientific Reports, 2020, 10, 26.	1.6	24
51	MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes. Translational Stroke Research, 2019, 10, 389-401.	2.3	21
52	The All66C polymorphism of the ATl receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. Journal of Hypertension, 2003, 21, 2085-92.	0.3	21
53	Activated protein C \hat{l}^2 -glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury. Blood, 2015, 126, 915-919.	0.6	20
54	Association of calprotectin with other inflammatory parameters in the prediction of mortality for ischemic stroke. Journal of Neuroinflammation, 2021, 18, 3.	3.1	20

#	Article	IF	CITATIONS
55	Vitamins C and E attenuate plasminogen activator inhibitor-1 (PAI-1) expression in a hypercholesterolemic porcine model of angioplasty. Cardiovascular Research, 2001, 49, 484-492.	1.8	19
56	Functional MMPâ€10 is required for efficient tissue repair after experimental hind limb ischemia. FASEB Journal, 2015, 29, 960-972.	0.2	19
57	Reduced high-density lipoprotein cholesterol: A valuable, independent prognostic marker in peripheral arterial disease. Journal of Vascular Surgery, 2017, 66, 1527-1533.e1.	0.6	19
58	Role of Extracellular Vesicles as Potential Diagnostic and/or Therapeutic Biomarkers in Chronic Cardiovascular Diseases. Frontiers in Cell and Developmental Biology, 2022, 10, 813885.	1.8	19
59	Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead. Journal of Medicinal Chemistry, 2015, 58, 2465-2488.	2.9	18
60	NADPH Oxidase Overactivity Underlies Telomere Shortening in Human Atherosclerosis. International Journal of Molecular Sciences, 2020, 21, 1434.	1.8	18
61	Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. Cardiovascular Research, 2004, 63, 176-185.	1.8	17
62	Recent progress in translational research on neurovascular and neurodegenerative disorders. Restorative Neurology and Neuroscience, 2017, 35, 87-103.	0.4	16
63	The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin. Journal of Thrombosis and Haemostasis, 2006, 4, 1798-1803.	1.9	15
64	Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke. Thrombosis Research, 2015, 136, 445-450.	0.8	15
65	New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator. Cardiovascular Research, 2017, 113, 1219-1229.	1.8	15
66	Selective increase of cardiomyocyte derived extracellular vesicles after experimental myocardial infarction and functional effects on the endothelium. Thrombosis Research, 2018, 170, 1-9.	0.8	12
67	Discovery and Safety Profiling of a Potent Preclinical Candidate, (4-[4-[[(3 <i>R</i>)-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]- <i>N</i> -methylbenzamide (CM-352), for the Prevention and Treatment of Hemorrhage. Journal of Medicinal Chemistry, 2015, 58, 2941-2957.	e) _{2.9}	11
68	Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction. BMC Neurology, 2015, 15, 111.	0.8	11
69	Urinary Extracellular Vesicles for Diabetic Kidney Disease Diagnosis. Journal of Clinical Medicine, 2021, 10, 2046.	1.0	10
70	Targeting \hat{I}^3 -secretases protect against angiotensin II-induced cardiac hypertrophy. Journal of Hypertension, 2015, 33, 843-850.	0.3	9
71	Association of SDF1 and MMP12 with Atherosclerosis and Inflammation: Clinical and Experimental Study. Life, 2021, 11, 414.	1.1	9
72	Evidence that Heparin but Not Hirudin Reduces PAI-1 Expression in Cultured Human Endothelial Cells. Thrombosis Research, 1999, 94, 137-145.	0.8	8

#	Article	IF	Citations
73	Inside the Thrombus: Association of Hemostatic Parameters With Outcomes in Large Vessel Stroke Patients. Frontiers in Neurology, 2021, 12, 599498.	1.1	8
74	Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery, 2022, 63, 648-656.	0.8	8
75	Association Between Matrix Metalloproteinase-10 Concentration and Smoking in Individuals Without Cardiovascular Disease. Revista Espanola De Cardiologia (English Ed), 2008, 61, 1267-1273.	0.4	6
76	Signature of subclinical femoral artery atherosclerosis in peripheral blood mononuclear cells. European Journal of Clinical Investigation, 2014, 44, 539-548.	1.7	6
77	High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients. BMC Neurology, 2019, 19, 167.	0.8	6
78	Respuesta. Revista Espanola De Cardiologia, 2008, 61, 327-328.	0.6	5
79	Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients. Journal of Critical Care, 2019, 51, 117-121.	1.0	5
80	Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage. Scientific Reports, 2020, 10, 10329.	1.6	5
81	Molecular and Cellular Mechanisms of Delayed Fracture Healing in <i>Mmp10</i> (Stromelysin 2) Knockout Mice. Journal of Bone and Mineral Research, 2021, 36, 2203-2213.	3.1	5
82	Hemostasis, inflammation and cardiovascular disease. Clinical Laboratory, 2002, 48, 463-70.	0.2	5
83	Folic acid and B vitamins improve hyperhomocysteinemia-induced cardiovascular risk profile in renal transplant recipients. Journal of Thrombosis and Haemostasis, 2007, 5, 1072-1076.	1.9	4
84	Altered atherosclerotic-related gene expression signature in circulating mononuclear leukocytes from hypercholesterolemic patients with low HDL cholesterol levels. International Journal of Cardiology, 2014, 173, 337-338.	0.8	4
85	High triglyceride-low HDL cholesterol lipid profile is associated with a dysregulated gene expression in mononuclear leukocyte from hypercholesterolemic patients. International Journal of Cardiology, 2015, 178, 102-104.	0.8	3
86	Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients. Biomarker Insights, 2007, $1, 165-73$.	1.0	3
87	Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents. ACS Medicinal Chemistry Letters, 2018, 9, 428-433.	1.3	2
88	Deficiency of MMP-10 Aggravates the Diseased Phenotype of Aged Dystrophic Mice. Life, 2021, 11, 1398.	1.1	2
89	Integrating Soluble Biomarkers and Imaging Technologies in the Identification of Vulnerable Atherosclerotic Patients. Biomarker Insights, 2006, 1, 117727190600100.	1.0	1
90	"Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients.―Reply to a comment by Geddings and Mackman. Thrombosis and Haemostasis, 2014, 111, 182-182.	1.8	1

#	Article	IF	CITATIONS
91	Matrix Metalloproteinase 10 Contributes to Choroidal Neovascularisation. Biomedicines, 2022, 10, 1557.	1.4	1
92	Markers of fibrinolytic potency and clotting activation in stable angina pectoris: role of urokinase, assessment of atrioventricular differences and correlation with coronary patency. Fibrinolysis and Proteolysis, 1999, 13, 133-138.	1.1	0
93	Corrigendum to "Preliminary characterisation of the promoter of the human p22phoxgene: Identification of a new polymorphism associated with hypertension―[FEBS Lett. 542 (2003) 27-31]. FEBS Letters, 2010, 584, 4709-4709.	1.3	O
94	CM-352 EFFICACY IN A MOUSE MODEL OF ANTICOAGULANT-ASSOCIATED INTRACRANIAL HAEMORRHAGE. Thrombosis and Haemostasis, 2022, 0, .	1.8	0
95	Hemostatic Biomarkers and Volumetry Help to Identify High-Risk Abdominal Aortic Aneurysms. Life, 2022, 12, 823.	1.1	0